Selling Your Veterinary Practice to Banfield: A Vet’s 2026 Guide

Key takeaways

• Banfield Pet Hospital is a Mars Veterinary Health-affiliated brand operating over 1,000 US locations, with most locations situated inside PetSmart retail stores.
• Banfield’s growth model is structurally different from the rest of the US veterinary acquirer pool. Banfield has historically grown through greenfield builds inside PetSmart rather than acquisitions of independent practices.
• For independent practice owners considering a Mars-affiliated sale, VCA (general practice) or BluePearl (specialty + emergency) are typically the more likely Mars-affiliated acquirers than Banfield.
• The wellness-plan business model — Banfield’s Optimum Wellness Plans deliver subscription-based preventive care alongside standard general practice services — is structurally distinct from the standalone-clinic model most independent practices operate under.
• If a Banfield acquisition conversation does surface, the practice profile likely fits a specific Banfield strategic interest outside the platform’s normal greenfield approach. The post-sale operating model would be structurally different than what most independent sellers experience joining VCA or other standalone-clinic-model buyers. The most reliable way to know what Banfield — or any Mars-affiliated entity — would actually pay for your specific practice is to run a structured competitive process. We call ours the Elite Selling System: we hand-select and vet every buyer who gets to bid, the way a doorman with a velvet rope lets in only the right people, then run a private bidding window inside that vetted group. Banfield is invited inside that rope only on practices that fit their specific strategic criteria — and when any Mars-affiliated entity bids against a curated group of qualified competitors, the number is reliably very different from what they would offer in a direct, single-bidder conversation.

The Banfield conversation looks different from every other US veterinary buyer conversation because Banfield itself is structurally different from every other US veterinary buyer category. Most consolidator conversations begin with a practice owner who has received outreach from a buyer actively building its acquisition pipeline.

Banfield‘s pipeline is built primarily through greenfield expansion inside PetSmart retail stores, not through acquisition of independent multi-doctor practices. The conversation that brings an independent practice owner to research Banfield as a potential buyer is usually one of two kinds: a practice owner doing diligence on the broader Mars-affiliated buyer category (where Banfield surfaces as a Mars sub-brand but isn’t the practical acquirer); or a practice owner whose specific practice profile happens to fit a Banfield strategic interest that runs outside the platform’s normal greenfield pattern.

For most independent practice owners, the practical takeaway is simple: the Mars-affiliated acquirer most likely to bid for your practice is VCA (if you’re a multi-doctor general practice) or BluePearl (if you’re a specialty + emergency hospital), not Banfield. That doesn’t make Banfield irrelevant to research — understanding the broader Mars Veterinary Health structure and where Banfield fits inside it informs how the seller thinks about any Mars-affiliated offer that does arrive.

But the time spent researching Banfield specifically as an acquirer is usually better spent researching VCA, BluePearl, and the broader Mars umbrella.

What follows is the picture I’d lay out over dinner if a vet asked me about Banfield specifically — what the platform actually is, why it operates the way it does, what an actual Banfield acquisition conversation would look like in the unusual cases where one happens, and how to think about Mars-affiliated alternatives that are structurally more likely to bid for an independent practice.

Quick facts on Banfield Pet Hospital

Banfield Pet Hospital operates over 1,000 US locations, with most locations situated inside PetSmart retail stores per Banfield company materials. The Banfield-PetSmart strategic distribution arrangement is a defining feature of the platform’s business model and predates Mars’s 2017 acquisition of VCA Inc.

Business model. Banfield‘s core revenue model emphasizes the Optimum Wellness Plan — a subscription-based preventive-care offering that bundles routine preventive services (exams, vaccinations, preventive diagnostics) into a monthly-payment structure. The wellness-plan model is structurally distinct from the standard fee-for-service model that characterizes most independent veterinary practices.

The wellness-plan business benefits from the PetSmart retail-foot-traffic exposure that pet owners encounter while shopping for pet products and services.

Growth pattern. Per Banfield company materials, the platform’s historical growth has been driven primarily by greenfield builds — new clinical locations constructed inside PetSmart stores as PetSmart’s retail footprint expanded. Independent practice acquisitions have been a meaningfully smaller component of Banfield’s growth than greenfield builds.

This contrasts sharply with VCA’s historical growth (driven primarily by acquisitions of independent practices) and reflects the structural difference between the Banfield business model and the standalone-clinic model.

Ownership. Banfield is part of Mars Veterinary Health, which is owned by Mars, Incorporated — the privately-held family-owned company owned by the Mars family of the United States. Mars Veterinary Health is the umbrella over Banfield, VCA Animal Hospitals, BluePearl Specialty + Emergency Pet Hospital, and Antech Diagnostics.

The Mars family ownership is structurally distinct from the PE-backed sponsorship that characterizes the rest of the US veterinary consolidator category — our Mars Veterinary Health buyer profile covers the family-owned-strategic dimensions in depth.

Most important practical fact. For independent practice owners considering selling, Banfield is unlikely to be the most natural Mars-affiliated buyer. The Mars-affiliated entity most likely to bid for an independent multi-doctor general practice is VCA. The Mars-affiliated entity most likely to bid for an independent specialty + emergency hospital is BluePearl.

Banfield’s growth model and PetSmart-distribution focus mean independent-practice acquisitions are unusual rather than typical at Banfield.

When would a Banfield acquisition conversation actually happen?

For most independent practice owners, the answer is “probably not.” But the unusual cases worth understanding:

Strategic-fit acquisitions. Banfield occasionally evaluates strategic acquisitions where the acquired practice’s profile fits a specific Banfield strategic interest — typically practices in retail-adjacent locations, practices with established wellness-plan or membership-driven revenue models, or practices that fit a regional expansion priority that greenfield builds inside PetSmart can’t address. These acquisitions are not the platform’s main growth engine, but they do happen.

Larger multi-location platforms. For larger multi-location platforms that align with Banfield‘s broader operational footprint, Banfield’s institutional capital position (through Mars) can support active bidding. These are unusual transactions and would typically run through the broader Mars Veterinary Health acquisition framework rather than Banfield’s standalone deal team.

Special situations. Occasional special-situation acquisitions arise — distressed sales, founder-retirement transitions with specific operational fit, regional expansions tied to PetSmart distribution decisions — where Banfield‘s strategic interests align with a particular practice. The volume is meaningfully low.

For most independent practice owners receiving Mars-affiliated outreach, the practical acquirer will be VCA or BluePearl, not Banfield. If an independent practice owner does receive direct Banfield outreach, that’s a signal the practice has a specific strategic fit worth understanding — and a properly run competitive process becomes even more important to clarify what the practice’s value actually is across the broader buyer pool.

What Banfield actually pays for veterinary practices (where it bids)

The consistent pattern we see. When any Mars-affiliated entity — including Banfield in the unusual cases where Banfield bids — receives a direct conversation with a practice owner, the offer reflects the leverage the buyer perceives. A single Mars-affiliated bidder facing no visible competition has no structural reason to put forward their strongest cash percentage, tightest brand-handling language, or most flexible operational protective provisions in the first conversation.

Inside a properly structured competitive process those dimensions move. The pattern is consistent across the Mars-affiliated category — VCA, BluePearl, and (where applicable) Banfield all calibrate to the competitive room.

Banfield does not publish a standard price sheet for the small subset of acquisitions it does pursue. Per industry M&A commentary (Octus, Capstone Partners, 2025-2026), competitive outcomes for strong multi-doctor general practices in the $2 million-plus revenue range typically land in the low-teens EBITDA range across the major buyer pool — Mars-affiliated entities included.

The actual number depends heavily on whether other buyers are at the table and on the specific strategic fit that prompted Banfield’s interest in the first place.

For specialty + emergency platforms, the more relevant Mars-affiliated bidder is BluePearl, not Banfield. The specialty footprint sits within BluePearl rather than Banfield’s PetSmart-distribution model.

For larger multi-location groups, the broader Mars Veterinary Health acquisition framework — typically led by VCA’s institutional acquisition team or the Mars Veterinary Health corporate development team — is more likely to be the practical acquirer than Banfield.

The Mars-affiliated cash-at-close reality

For any Mars-affiliated transaction including the unusual Banfield case, the cash-at-close component follows the broader Mars-affiliated template documented in 2025-2026 healthcare M&A commentary (Dechert LLP, Holland & Knight, Capstone Partners) — majority of deal value lands as cash at closing, with the remainder split among earnout, rollover or partnership equity, and occasional seller notes.

The Mars family-owned strategic ownership matters specifically for the rollover-equity dimension. A rollover into Mars-affiliated equity sits inside a platform whose ultimate owner (the Mars family) has no defined exit cycle.

The standard rollover-into-PE-platform exit mechanics don’t map directly onto Mars’s family-ownership posture. Sellers retaining equity in any Mars-affiliated transaction should negotiate explicit liquidity mechanics — defined put/call windows, formula-based buyout prices, milestone-tied liquidity events — rather than relying on a platform-level exit event that may not occur on a defined timeline.

For more on the Mars-affiliated rollover-equity dynamics in depth, see our Mars Veterinary Health buyer profile.

How Banfield’s integration would work (in the unusual acquisition cases)

In the small number of cases where Banfield does acquire an independent practice, the integration transitions the acquired location into the Banfield operational framework. That transition is structurally more significant than the integrations at VCA or BluePearl because the Banfield model differs more from the standalone independent-practice model than the VCA or BluePearl models do.

Wellness-plan model integration. The Banfield Optimum Wellness Plan subscription model is the core revenue framework across Banfield locations. An acquired independent practice would typically transition revenue mechanics toward the wellness-plan model, which represents a meaningful operational shift from standard fee-for-service practices.

Brand handling. Per the Banfield model, locations operate under the Banfield brand rather than maintaining local independent branding. An acquired independent practice would typically transition to Banfield branding, which contrasts with the brand-preservation defaults at most non-Banfield Mars-affiliated and non-Mars-affiliated US veterinary acquirers.

PetSmart-distribution integration. Where applicable, Banfield acquisitions may involve relocation or co-location with a PetSmart retail store as part of the broader strategic-distribution model. This is more relevant for greenfield-adjacent scenarios than for typical independent-practice acquisitions.

Operational standardization. Banfield‘s institutional model includes well-developed operational standards across clinical protocols, staffing models, scheduling, and customer-experience infrastructure. An acquired independent practice would experience operational standardization that’s more comprehensive than at most non-Banfield acquirers.

For most independent practice owners, the structural differences between the Banfield model and the standalone independent-practice model make a Banfield acquisition a meaningful operating-model transition rather than a continuation under new ownership. That’s an important consideration when evaluating whether a Banfield acquisition is the right fit, in the unusual cases where one is on the table.

What to consider if a Banfield conversation actually surfaces

For independent practice owners who do receive Banfield outreach or are evaluating a Banfield-affiliated offer, six considerations.

Confirm the strategic fit. Banfield’s acquisition criteria differ from the rest of the buyer pool. The conversation only makes sense if the practice’s profile fits a specific Banfield strategic interest.

Understanding why Banfield is interested — and what specifically about your practice fits their model — is the first question to ask explicitly.

Compare against VCA and BluePearl. The natural alternative Mars-affiliated acquirers for most independent practices are VCA (general practice) and BluePearl (specialty + emergency). A properly run competitive process should include VCA or BluePearl as Mars-affiliated comparison points, not just Banfield in isolation.

Our VCA buyer profile and the BluePearl dimensions within the Mars Veterinary Health buyer profile cover those alternatives.

Evaluate the brand-and-model transition. A Banfield acquisition transitions the practice to the Banfield brand and wellness-plan operating model. That transition is more significant than the brand-transitions at VCA acquisitions (which keep the standalone-clinic model intact even while transitioning the brand).

For sellers with decades of local goodwill and a fee-for-service practice character, the operational transition is the central consideration.

Standard economic terms. Cash-at-close percentage, earnout structure, rollover-equity terms, and non-compete scope follow the broader Mars-affiliated template. See the Mars Veterinary Health buyer profile for the negotiation framework.

Post-sale role and clinical autonomy. Banfield‘s institutional operational standards include more comprehensive standardization than most acquirers. Sellers expecting post-sale clinical autonomy comparable to what they had as independent owners should negotiate explicit carve-outs, recognizing that Banfield’s model has less operational flexibility than the standalone-clinic model alternatives.

Run the broader competitive process. Even where a Banfield conversation is genuine, running a competitive process that includes the non-Banfield Mars-affiliated alternatives (VCA, BluePearl) and the broader US buyer pool produces the necessary comparison framework. Banfield is rarely the right choice in isolation; it may be the right choice in context, but the context only emerges from competitive comparison.

Should I take a Banfield offer or run a competitive process?

For the unusual cases where a Banfield offer surfaces, the competitive process is even more important than usual — because Banfield is structurally outside the normal independent-practice acquisition framework, and the comparison points that surface in a properly run process clarify whether the Banfield model is genuinely the right fit for the seller’s specific situation.

The comparison set should include VCA (the natural Mars-affiliated alternative for general practice), BluePearl where applicable (for specialty platforms), and the broader US buyer pool — NVA, VetCor, AmeriVet, PetVet, Mission Pet Health, Thrive, Alliance, and the smaller PE-backed groups. Each of these alternatives operates a standalone-clinic model that’s structurally closer to most independent practices than the Banfield model is, which makes the comparison particularly important for evaluating whether the Banfield-specific strategic-fit case actually outweighs the operating-model transition cost.

What our Elite Selling System actually does

For the unusual case of a Banfield-affiliated transaction, our process emphasizes the comparison framework that clarifies whether the Banfield-specific case actually fits the seller’s situation.

Phase one — the strategic-fit audit. We deconstruct what specifically about the practice prompted Banfield’s interest, and we map that against the strategic fit at VCA, BluePearl, and the broader buyer pool. If Banfield’s interest is genuinely unique (a PetSmart-adjacency consideration, a wellness-plan-driven revenue profile, a regional strategic-distribution priority), we understand the case for the unusual transaction.

If the strategic fit isn’t unique, the comparison to non-Banfield alternatives will surface better-fitting buyers.

Phase two — the curated bidder mix. From the 42-plus veterinary consolidators TE tracks, the bidder mix for a Banfield-affiliated scenario typically emphasizes the Mars-affiliated alternatives (VCA, BluePearl) and the broader brand-preservation buyer pool (NVA, VetCor, AmeriVet, Mission Pet Health, others). The competitive process tests whether the standalone-clinic-model alternatives offer a better fit than the Banfield model transition.

Phase three — the model-fit comparison. Bidders return full term sheets. The seller sees side-by-side comparisons across not just the economic terms but the operating-model differences — standalone clinic versus PetSmart-distribution, fee-for-service versus wellness-plan, brand preservation versus brand transition.

The decision is often clearer in the comparison than it appears in isolation.

The economic result holds across deal types: practices in the qualifying revenue band that run our process consistently clear materially better total economic outcomes — and just as important, find a buyer whose operating-model fits the seller’s situation — than the same practice would have cleared by signing the direct first-bidder term sheet without exploring the field.

Closing thought

Banfield Pet Hospital is one of the larger US veterinary brands by location count, but its growth-via-greenfield-inside-PetSmart model makes it an unusual acquirer for most independent practices. For most owners researching Mars-affiliated alternatives, VCA (general practice) and BluePearl (specialty + emergency) are the structurally more relevant Mars-affiliated buyers.

If a Banfield conversation does surface for your specific practice, the strategic-fit case behind it deserves explicit investigation — understanding what about your practice fits Banfield’s unusual acquisition criteria is the foundation of any well-negotiated outcome. The broader Mars-affiliated alternatives (VCA, BluePearl) and the non-Mars-affiliated buyer pool typically offer structurally closer fits to most independent practices than the Banfield model does.

If a Banfield offer is on your desk right now — or if you’ve been weighing the Banfield-vs-VCA-vs-BluePearl question among Mars-affiliated alternatives — the highest-leverage move is to put the actual alternatives in front of you in a structured comparison. Get a Free Practice Value Estimate and we’ll lay out the Mars-affiliated and broader buyer-pool comparison we would for a client across a dinner table.

Sources

Industry M&A research and valuation data

1. Capstone Partners. Pet Sector M&A Update — April 2026. Capstone Partners industry research.
2. Octus. Veterinary Services Roll-Up Coverage, 2025-2026. Octus credit research and industry commentary.
3. Dechert LLP. Healthcare M&A: 2025-2026 Trends and Outlook. Dechert healthcare practice publications.
4. Holland & Knight. Healthcare Private Equity 2025-2026 Commentary. Holland & Knight healthcare practice publications.

Banfield, Mars Veterinary Health, and parent company materials

5. Banfield Pet Hospital. About Banfield and US footprint. Banfield company materials, 2024-2026.
6. Mars Veterinary Health. About Mars Veterinary Health US division and brand portfolio. Mars Veterinary Health company materials, 2024-2026.
7. Mars, Incorporated. Privately-held family ownership and corporate structure. Mars company materials, 2024-2026.

Veterinary practice operations, benchmarks, and profession data

8. iVET360. State of the Veterinary Industry — 2026 Industry Report. iVET360 industry research.
9. American Veterinary Medical Association (AVMA). 2026 AVMA Veterinary Economic Report. AVMA economic research.